Search clinical trials for: AraC

Total 1049 results

Sun Yat-sen University

Unknown

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Relapse Leukemia

China
Eleos, Inc.

Withdrawn

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

Acute Myelogenous Leukemia
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Leukemia

United States
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals

Terminated

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid Neoplasm

United States
The Lymphoma Academic Research Organisation

Active, not recruiting

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Mantle Cell Lymphoma

France, Spain, Belgium, Netherlands, Germany, Poland, Portugal
Massachusetts General Hospital
AbbVie

Recruiting

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Acute Myeloid Leukemia

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Acute Myeloid Leukemia | Leukemia | AML

United States
University of Illinois at Chicago
Teva Pharmaceuticals USA

Terminated

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

Acute Myeloid Leukemia

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (MOHEL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Hemophagocytic Lymphohistiocytosis (HLH) | Non Hodgkins Lymphoma | Familial Hemophagocytic Lymphohistiocytosis (FLH) | Viral-associated Hemophagocytic Syndrome (VAHS) | X-linked Lymphoproliferative...

United States
M.D. Anderson Cancer Center
Bayer

Completed

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Acute Myeloid Leukemia | AML | Myelodysplastic Disorders

United States
National Cancer Institute (NCI)

Terminated

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Completed

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Withdrawn

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
National Cancer Institute (NCI)

Recruiting

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Actinic Keratosis

United States
LanZhou University

Recruiting

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Acute Myeloid Leukemia

China
Sellas Life Sciences Group

Active, not recruiting

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL)

Acute Myeloid Leukemia

United States, Spain, France, Taiwan, India, Hungary, Poland, Germany, Serbia, Greece
Columbia University
The Leukemia and Lymphoma Society

Completed

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

Acute Myeloid Leukemia

United States
C. Babis Andreadis
GlaxoSmithKline; University of California, San Francisco

Completed

Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large Cell Lymphoma Relapsed/Refractory

United States
M.D. Anderson Cancer Center

Completed

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Leukemia

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Schering-Plough

Completed

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

Chronic Myeloid Leukemia

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

Leukemia

United States, Canada, Sweden
National Cancer Institute (NCI)

Completed

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Ohio State University Comprehensive Cancer Center
Incyte Corporation; Jazz Pharmaceuticals

Recruiting

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Secondary Acute Myeloid Leukemia | Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic... and other conditions

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Terminated

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE (REGALE)

Leukemia | Myeloproliferative Disorders | Hodgkin Lymphoma | Non Hodgkin Lymphoma

United States
Washington University School of Medicine

Terminated

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

Chronic Myelomonocytic Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
European Mantle Cell Lymphoma Network
Lymphoma Study Association; German Low Grade Lymphoma Study Group

Unknown

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Lymphoma, Mantle-Cell

France, Germany, Poland
Shengjing Hospital

Not yet recruiting

Combination Therapy of Anthracyclines for Children With Nephroblastoma

0.5-14 Year Old Children With Nephroblastoma

China
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related

United States, Puerto Rico
Washington University School of Medicine

Withdrawn

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
Roswell Park Cancer Institute
Amgen

Completed

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Nohla Therapeutics, Inc.
National Cancer Institute (NCI); Fred Hutchinson Cancer Center

Completed

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Massachusetts General Hospital
Celgene Corporation

Terminated

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Acute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (VITAL)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic Syndrome | Myeloid Sarcoma | Acute Myeloid Leukemia With Multilineage Dysplasia

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
PrECOG, LLC.
Astellas Pharma Inc

Active, not recruiting

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Sumitomo Pharma America, Inc.

Terminated

Alvocidib Biomarker-driven Phase 2 AML Study

Acute Myeloid Leukemia

United States, Spain, Canada, United Kingdom
National Research Center of Surgery, Russia
Federal Centre of High Medical Technologies of the RF Ministry of Public...

Unknown

Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation) (PULVAB)

Myocardial Ischemia | Cardiovascular Diseases | Arrhythmias, Cardiac | Postoperative Atrial Fibrillation

Russian Federation
Institute of Hematology & Blood Diseases Hospital

Unknown

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Acute Myeloid Leukemia

China
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
Chen Suning

Active, not recruiting

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Chemotherapy Effect | AML, Adult

China

Search clinical trials for: AraC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations